Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?

Meltzer, Herbert Y.; Sumiyoshi, Tomiki

doi:10.1016/j.bbr.2008.05.016

Cited by 157 publications

(96 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, ziprasidone also acts on 5HT 1A receptor as the agonist in human brain tissue, which has been identified as a potential therapeutic target for the treatment of schizophrenia in previous studies (Bantick, Deakin, & Grasby, 2001;Millan, 2000). However, the contribution of 5HT 1A receptor in the CIAS is still ambiguous, further study of the mechanism underlying the 5HT 1A to improve CIAS is warranted (Meltzer & Sumiyoshi, 2008;Ögren et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

Effects of haloperidol, olanzapine, ziprasidone, and PHA‐543613 on spatial learning and memory in the Morris water maze test in naïve and MK‐801‐treated mice

et al. 2017

View full text Add to dashboard Cite

Introduction Cognitive impairment is the core symptom of schizophrenia, significantly impacting the functional outcome. Improvement of cognitive function has been an important aspect of the treatment of schizophrenia. Therefore, this study is to demonstrate the effects of first‐generation antipsychotic haloperidol, second‐generation antipsychotic olanzapine and ziprasidone, and alpha‐7 nicotinic acetylcholine receptor agonist PHA ‐543613 on spatial learning and memory. Material and Methods C57 BL /6 mice received intraperitoneal injections of haloperidol (2 mg/kg), olanzapine (2.5 mg/kg), ziprasidone (2 mg/kg), and PHA ‐543613 (1 mg/kg), and cognitive dysfunctions were induced by MK ‐801 (0.1 mg/kg). Morris water maze was used for investigating the effects of all agents. Results Mk‐801 significantly increased the mean escape latency to the platform and decreased the number of platform area crossings. Ziprasidone had no effect on the mean escape latency to platform and the number of platform area crossings in naïve mice, but haloperidol, olanzapine, and PHA ‐543613 did not. Haloperidol and olanzapine significantly increased the mean escape latency to platform and decreased the number of platform area crossings, while ziprasidone and PHA ‐543613 did not. All the agents had no effect on swimming speed. Conclusions Ziprasidone and alpha‐7 nicotinic acetylcholine receptor agonist PHA ‐543613 might be helpful in the treatment of CIAS .

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of haloperidol, olanzapine, ziprasidone, and PHA‐543613 on spatial learning and memory in the Morris water maze test in naïve and MK‐801‐treated mice

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Among the subtypes of 5-HT receptors (Fig. 4), 5-HT 1A , 5-HT 2A , 5-HT 6 , and 5-HT 7 receptors have been shown to be associated with cognitive effects of AAPDs, suggesting pivotal roles for the serotonergic system in cognitive symptoms of schizophrenia (Sumiyoshi T. et al 2007a, Meltzer and Sumiyoshi 2008. Fig.…”

Section: -Ht Receptors and Cognitive Functionmentioning

confidence: 99%

Serotonin-1A Receptors and Cognitive Enhancement in Schizophrenia: Role for Brain Energy Metabolism

Sumiyoshi¹,

Uehara²

2012

Schizophrenia in the 21st Century

Self Cite

View full text Add to dashboard Cite

“…Contrary to this finding, is a study that reported the impaired cognition in healthy volunteers following 5-HT 1A agonist administration [87]. In sum, it seems that of 5-HT 1A receptor stimulation may ameliorate cognitive deficits in schizophrenia (see for review [63,67,88]). …”

Section: -Ht 1a Receptor Agonists In Schizophreniamentioning

confidence: 59%

“…Stimulation by extracellular 5-HT or by a 5-HT 1A receptor agonist, suppresses the firing of 5-HT neurons. Postsynaptic 5-HT 1A receptors are localised on pyramidal as well as GABAergic interneurons in the hippocampus, frontal and entorhinal cortex, amygdale which have been described as key areas involved in physiopathology of schizophrenia [63]. Postmortem and PET studies have shown that 5-HT 1A receptors binding is increased in the frontal cortex of schizophrenic patients ( [64][65][66]; for a review see [67]).…”

Section: -Ht 1a Receptor Agonists In Schizophreniamentioning

confidence: 99%

“…Clinical studies have reported a beneficial therapeutic effect of the simultaneously administration of a typical or atypical antipsychotic and a 5-HT 1A agonist (like tandospirone or buspirone) on cognitive deficits, including verbal learning and memory (see for review [63]). Contrary to this finding, is a study that reported the impaired cognition in healthy volunteers following 5-HT 1A agonist administration [87].…”

Section: -Ht 1a Receptor Agonists In Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents~!2009-12-17~!2010-04-07~!2010-07-20~!

Etiévant¹

2010

TONEUROPPJ

View full text Add to dashboard Cite

Abstract:The therapeutic efficacy of current antipsychotic or antidepressant agents still present important drawbacks such as delayed onset of action and a high percentage of non-responders. Despite significant advancements in the development of new drugs with more acceptable side-effect profiles, patients with schizophrenia or major depression experience substantial disability and burden of disease. The present review discusses the usefulness of partial dopamine D 2 /serotonin 5-HT 1A receptors agonists in the treatment of schizophrenia, major depression and bipolar disorder as well as in Parkinson's disease. Partial agonists can behave as modulators since their intrinsic activity or efficacy of a partial agonist depends on the target receptor population and the local concentrations of the natural neurotransmitter. Thus, these drugs may restore adequate neurotransmission while inducing less side effects. In schizophrenia, partial DA D 2 /5-HT 1A receptor agonists (like aripiprazole or bifeprunox), by stabilizing DA system via a preferential reduction of phasic DA release, reduce side effects i.e. extrapyramidal symptoms and improve cognition by acting on 5-HT 1A receptors. Aripiprazole appears also as a promising agent for the treatment of depression since it potentiates the effect of SSRIs in resistant treatment depression. Concerning bipolar disorders aripiprazole may have only a benefit effect in the treatment of manic episodes. Conversely, treatment of Parkinson's disease with partial DA D 2 /5-HT 1A receptor agonists remains still experimental. However several studies suggest that these drugs decrease usually observed side effects (dyskinesia, psychoticlike symptoms) in Parkinson's disease treatment. Hence, these relatively recent researches provide an exciting future in the discovery of novel stabilizators agents for the management of the latter diseases.

show abstract

Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?

Cited by 157 publications

References 59 publications

Effects of haloperidol, olanzapine, ziprasidone, and PHA‐543613 on spatial learning and memory in the Morris water maze test in naïve and MK‐801‐treated mice

Effects of haloperidol, olanzapine, ziprasidone, and PHA‐543613 on spatial learning and memory in the Morris water maze test in naïve and MK‐801‐treated mice

Serotonin-1A Receptors and Cognitive Enhancement in Schizophrenia: Role for Brain Energy Metabolism

Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents~!2009-12-17~!2010-04-07~!2010-07-20~!

Contact Info

Product

Resources

About